Chidamide in Patients With Recurrent and Refractory Diffuse Large b

Enrolling by invitationOBSERVATIONAL
Enrollment

169

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2026

Conditions
Diffuse Large B-cell Lymphoma
Interventions
DRUG

Chidamide

Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses

DRUG

Lenalidomide

Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle

DRUG

Rituximab

Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle

Trial Locations (1)

Unknown

Second Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Soochow University

OTHER